Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

@article{ElSahwi2010OverexpressionOE,
  title={Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).},
  author={Karim S El-Sahwi and Stefania Bellone and Emiliano Cocco and Francesca Casagrande and Marta Bellone and Maysa Abu-Khalaf and Natalia Buza and Fattaneh A. Tavassoli and Pei Hui and Dominik Ruettinger and D A Silasi and Masoud Azodi and Peter Edward Schwartz and Thomas J. Rutherford and Sergio L Pecorelli and Alessandro D Santin},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 1},
  pages={57-66}
}
We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human monoclonal antibody against EpCAM, in uterine serous papillary carcinoma (USPC). EpCAM expression was evaluated by real-time PCR and immunohistochemistry in a total of 56 USPC fresh-frozen biopsies and paraffin-embedded tissues. EpCAM surface expression was also evaluated by flow cytometry and immunohistochemistry in six USPC cell lines. Sensitivity to MT201 antibody… CONTINUE READING
19 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…